RGD Reference Report - Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy.

Authors: Yuan, X  Liao, Z  Liu, Z  Wang, LE  Tucker, SL  Mao, L  Wang, XS  Martel, M  Komaki, R  Cox, JD  Milas, L  Wei, Q 
Citation: Yuan X, etal., J Clin Oncol. 2009 Jul 10;27(20):3370-8. Epub 2009 Apr 20.
RGD ID: 4145136
Pubmed: PMID:19380441   (View Abstract at PubMed)
PMCID: PMC4385796   (View Article at PubMed Central)
DOI: DOI:10.1200/JCO.2008.20.6763   (Journal Full-text)

PURPOSE: In search of reliable biologic markers to predict the risk of normal tissue damage by radio(chemo)therapy before treatment, we investigated the association between single nucleotide polymorphisms (SNPs) in the transforming growth factor 1 (TGFbeta1) gene and risk of radiation pneumonitis (RP) in patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Using 164 available genomic DNA samples from patients with NSCLC treated with definitive radio(chemo)therapy, we genotyped three SNPs of the TGFbeta1 gene (rs1800469:C-509T, rs1800471:G915C, and rs1982073:T869C) by polymerase chain reaction restriction fragment length polymorphism method. We used Kaplan-Meier cumulative probability to assess the risk of grade > or = 3 RP and Cox proportional hazards analyses to evaluate the effect of TGFbeta1 genotypes on such risk. RESULTS: There were 90 men and 74 women in the study, with median age of 63 years. Radiation doses ranging from 60 to 70 Gy (median = 63 Gy) in 30 to 58 fractions were given to 158 patients (96.3%) and platinum-based chemotherapy to 147 (89.6%). Grade > or = 2 and grade > or = 3 RP were observed in 74 (45.1%) and 36 patients (22.0%), respectively. Multivariate analysis found CT/CC genotypes of TGFbeta1 rs1982073:T869C to be associated with a statistically significantly lower risk of RP grades > or = 2 (hazard ratio [HR] = 0.489; 95% CI, 0.227 to 0.861; P = .013) and grades > or = 3 (HR = 0.390; 95% CI, 0.197 to .774; P = 0.007), respectively, compared with the TT genotype, after adjustment for Karnofsky performance status, smoking status, pulmonary function, and dosimetric parameters. CONCLUSION: Our results showed that CT/CC genotypes of TGFbeta1 rs1982073:T869C gene were associated with lower risk of RP in patients with NSCLC treated with definitive radio(chemo)therapy and thus may serve as a reliable predictor of RP.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
TGFB1HumanRadiation Pneumonitis susceptibilityIAGP DNA:SNP:exon:869T>C (rs1982073) (human)RGD 
Tgfb1RatRadiation Pneumonitis susceptibilityISOTGFB1 (Homo sapiens)DNA:SNP:exon:869T>C (rs1982073) (human)RGD 
Tgfb1MouseRadiation Pneumonitis susceptibilityISOTGFB1 (Homo sapiens)DNA:SNP:exon:869T>C (rs1982073) (human)RGD 

Objects Annotated

Genes (Rattus norvegicus)
Tgfb1  (transforming growth factor, beta 1)

Genes (Mus musculus)
Tgfb1  (transforming growth factor, beta 1)

Genes (Homo sapiens)
TGFB1  (transforming growth factor beta 1)


Additional Information